Skip to content

Categories:

Category Archives: Fuad El-Hibri

Emergent BioSolutions to Release Fourth Quarter and Full Year 2011 Financial Results and Conduct a Conference Call on March 8, 2012 February 2, 2012
Posted in Chief executive officer, Chief financial officer, El-Hibri, Emergent BioSolutions, Fuad El-Hibri, Shareholders.
No comments
Fuad El-Hibri and the TAKREEM Achievement Awards November 7, 2011
Posted in Arab, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri.
No comments
Fuad El-Hibri on Arabian Business Power 500 October 27, 2011
Posted in Arab, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri.
No comments
FUAD EL-HIBRI TO AWARD 2011 EL-HIBRI PEACE EDUCATION PRIZE TO GENE SHARP September 30, 2011
Posted in Chief executive officer, El-Hibri Peace Education Prize, Emergent BioSolutions, Fuad El-Hibri.
No comments
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London September 21, 2011
Posted in Chief executive officer, Emergent BioSolutions, Financial Results, Fuad El-Hibri, Investors.
No comments
Fuad El-Hibri Interviewed by Ricardo Karam September 7, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri.
No comments
Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma August 24, 2011
Posted in Chief Medical Officer, Chief executive officer, El-Hibri, Emergent BioSolutions, Fuad El-Hibri, Healthcare, Lymphoma.
No comments
Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference August 15, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Investors.
No comments
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors June 20, 2011
Posted in Chief executive officer, Emergent BioSolutions, Entrepreneur, Fuad El-Hibri.
No comments
Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation June 10, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, NuThrax, U.S. Food and Drug Administration.
No comments
Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule June 7, 2011
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Food and Drug Administration, Fuad El-Hibri.
No comments
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference June 1, 2011
Posted in Business, El-Hibri, Financial Performance, Fuad El-Hibri, Healthcare Conference, Investors.
No comments
Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial May 2, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, South Africa.
No comments
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress April 15, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, biotechnology.
No comments
Emergent BioSolutions Reports Financial Results for Full Year 2010 April 13, 2011
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Financial Results, Fuad El-Hibri, Trubion Pharmaceuticals.
No comments
Emergent BioSolutions Observes World TB Day Launches “OETC: Endeavor to End Tuberculosis,” a video to raise public awareness of TB March 25, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, World Health Organization, World TB.
No comments
Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine March 3, 2011
Posted in Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri.
No comments
Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10 February 25, 2011
Posted in Biotechnology and Pharmaceuticals, Chief executive officer, El-Hibri, Emergent BioSolutions, Fuad El-Hibri.
No comments
Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia February 1, 2011
Posted in Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Lymphocyte, Tuberculosis Vaccine.
No comments
CEO took roundabout path to Emergent January 7, 2011
Posted in Business, Chief executive officer, El-Hibri, Emergent BioSolutions, Entrepreneur, Food and Drug Administration, Fuad El-Hibri, Trubion Pharmaceuticals, United States, United States Department of Health and Human Services, Vaccine, Yale University, biotechnology.
No comments
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine January 4, 2011
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri.
No comments
Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting December 15, 2010
Posted in American Society of Hematology, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Hematology.
No comments
Fuad El-Hibri Recognized by Vilcek Foundation December 10, 2010
Posted in Chief executive officer, El-Hibri, El-Hibri Fuad, El-Hibri Peace Education Prize, Emergent BioSolutions, Fuad El-Hibri, Peace Education.
No comments
Fuad El-Hibri and the International Biomedical Research Alliance November 13, 2010
Posted in BioThrax, Chief executive officer, El-Hibri, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States.
No comments
Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals November 4, 2010
Posted in Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Trubion Pharmaceuticals.
No comments